CSP Mylan SAS AT Csp- Labo 274, Pharmaceutical Import Profile — France (DGFT 2022–2026)

Name: CSP Mylan SAS AT Csp- Labo 274, Pharmaceutical Import Records from India — 6 Products, $8.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

CSP Mylan SAS AT Csp- Labo 274, — Pharmaceutical Importer Profile (2026) | 6 Products, $8.0M Trade | TransData Nexus

CSP Mylan SAS AT Csp- Labo 274,

Pharmaceutical Importer · France · Diabetes & Endocrine Focus · $8.0M Total Trade · DGFT Verified

CSP Mylan SAS AT Csp- Labo 274, is a pharmaceutical importer based in France with a total trade value of $8.0M across 6 products in 5 therapeutic categories. Based on 160 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. CSP Mylan SAS AT Csp- Labo 274, sources from 5 verified Indian suppliers, with Mylan Laboratories Limited accounting for 89.1% of imports.

CSP Mylan SAS AT Csp- Labo 274, — Import Portfolio & Supplier Network

CSP Mylan SAS AT Csp- Labo 274, import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to CSP Mylan SAS AT Csp- Labo 274,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Mylan Laboratories Limited	$14.2M	457	89.1%
Granules India Limited	$1.0M	27	6.5%
Unichem Laboratories Limited	$425.2K

What Formulations Does CSP Mylan SAS AT Csp- Labo 274, Import?

Formulation	Value	Ships
Irbesartan / hydrochlorothiazide mylan	$300.0K	6
Amlodipine / valsartan mylan 5 MG / 80	$263.9K	9
Acamprosate mylan 333 MG 60bl TAB	$250.0K	5
Clopidogrel / acide acetylsalicylique	$250.0K	5
Sitagliptine viatris 100 MG 28bl TAB	$213.9K	5
Verapamil mylan pharma l.p. 240 MG	$200.0K	4
Sitagliptin TAB 100 MG 28 bl fr via	$200.0K	4
Rosuvastatine mylan 5 MG TAB 90 bl	$186.0K	6
Rosuvastatine mylan 5 MG 30 bl TAB	$184.4K	5
Irbesartan/hydrochlorothiazide mylan	$178.2K	4
Risperidone mylan 1 MG 60 bl TAB packs	$160.6K	4
Pregabaline mylan 75 MG 56 bl cap	$160.5K	4
Risperidone mylan 4 MG 30 bl TAB packs	$156.3K	4
Amlodipine/valsartan mylan 10 MG/160 MG	$152.7K	4
Verapamil mylan pharma l.p. 240 MG	$150.0K	3

CSP Mylan SAS AT Csp- Labo 274, imports 337 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$3.3M	65	0.7%	16
2	Irbesartan	Cardiovascular	$2.1M	42	1.1%	11
3	Hydrochlorothiazide	Diuretics	$1.3M	26	0.3%	16
4	Ezetimibe	Lipid & Metabolism	$600.0K	12	0.1%	14
5	Sitagliptin	Diabetes & Endocrine	$500.0K	10	0.7%	18
6	Terbinafine	Antifungals	$250.0K	5	0.9%	15

CSP Mylan SAS AT Csp- Labo 274, imports 6 pharmaceutical products across 5 categories into France totaling $8.0M.

CSP Mylan SAS AT Csp- Labo 274, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

CSP Mylan SAS AT Csp- Labo 274, based in Cournon-d'Auvergne, France, is a pharmaceutical importer specializing in the acquisition of finished pharmaceutical formulations from international suppliers. As part of the CSP Group, a family-operated company founded in 1951, it plays a significant role in the French pharmaceutical distribution network. The CSP Group is recognized as a leading pharmaceutical depository in France and Europe, serving a diverse clientele that includes pharmaceutical laboratories, wholesale distributors, pharmacies, healthcare establishments, and supermarkets.

CSP Mylan SAS AT Csp- Labo 274's operations are integral to the CSP Group's extensive logistics and distribution capabilities. The CSP Group manages a total of 200,000 m² of warehouse space across France and the Benelux region, with facilities in Cournon-d'Auvergne, Moussy-le-Neuf near Paris, and Belgium. This infrastructure supports the efficient importation and distribution of pharmaceutical products, ensuring timely delivery to various stakeholders in the healthcare sector.

2Distribution Network

CSP Mylan SAS AT Csp- Labo 274 operates within the CSP Group's extensive distribution network, which encompasses over 200,000 m² of warehouse space across France and the Benelux region. Key facilities include the 82,000 m² site in Cournon-d'Auvergne near Clermont-Ferrand, the 83,000 m² warehouse in Moussy-le-Neuf near Paris, and a 15,000 m² facility in Belgium. These strategically located warehouses enable CSP to efficiently manage the importation, storage, and distribution of pharmaceutical products throughout France and neighboring countries.

3Industry Role

CSP Mylan SAS AT Csp- Labo 274 functions as a pharmaceutical importer within the French supply chain, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. Its role is pivotal in ensuring the availability of a wide range of pharmaceutical products in the French market, thereby supporting the operations of pharmacies, hospitals, and other healthcare providers. By leveraging the CSP Group's extensive logistics and distribution network, the company contributes to the efficient delivery of medications to various stakeholders in the healthcare sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — CSP Mylan SAS AT Csp- Labo 274,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

CSP Mylan SAS AT Csp- Labo 274 demonstrates a high degree of sourcing concentration, with a total import value of $8.0 million USD from India over 160 shipments, primarily consisting of six products across five therapeutic categories. The top five products—Metformin, Irbesartan, Hydrochlorothiazide, Ezetimibe, and Sitagliptin—account for 96.9% of the total import value, indicating a focused procurement strategy. This concentration suggests a strategic choice to streamline operations and maintain strong supplier relationships, potentially enhancing negotiation leverage and ensuring consistent product quality. However, such dependency also exposes the company to risks associated with supply chain disruptions, price fluctuations, and regulatory changes affecting these specific products.

The shipment data reveals a stable relationship with key suppliers, notably Mylan Laboratories Limited, which accounts for 89.1% of the total import value. This long-term partnership likely contributes to operational efficiency and product consistency. Nonetheless, the limited number of suppliers and the high concentration of imports in a few products may pose challenges in mitigating supply chain risks and adapting to market changes.

2Supply Chain Resilience

CSP Mylan SAS AT Csp- Labo 274's supply chain resilience is closely tied to its sourcing strategy from India. The company's reliance on a limited number of suppliers, particularly Mylan Laboratories Limited, indicates a focused procurement approach. While this can lead to operational efficiencies and strong supplier relationships, it also presents challenges in terms of supply chain diversification. The lack of backup suppliers for key products may expose the company to risks associated with supply disruptions, price volatility, and regulatory changes affecting these suppliers. Additionally, the concentration of imports in specific formulations and therapeutic categories may limit the company's ability to adapt to shifts in market demand or regulatory requirements.

Importing Pharmaceuticals into France — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for France

1Regulatory Authority & Framework

In France, the primary regulatory authority overseeing pharmaceutical imports is the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM). ANSM is responsible for ensuring the safety, efficacy, and quality of medicines and health products available in the French market. Key legislation governing pharmaceutical imports includes the French Public Health Code, which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. The European Medicines Agency (EMA) also plays a significant role in harmonizing regulatory standards across EU member states, including France, facilitating the marketing authorization process for medicinal products.

For Indian generics to enter the French market, they must obtain marketing authorization from ANSM. This process involves submitting a comprehensive dossier that includes data on the quality, safety, and efficacy of the product. The dossier must demonstrate that the generic product is bioequivalent to the reference product, ensuring that it performs in the same manner as the original. The bioequivalence study should adhere to the guidelines set forth by ANSM and EMA, which may include requirements for clinical trials and other supporting data. Once approved, the product is granted a marketing authorization, allowing it to be imported and distributed within France.

2Import Licensing & GMP

CSP Mylan SAS AT Csp- Labo 274, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

CSP Mylan SAS AT Csp- Labo 274's product category focus—Diabetes & Endocrine (46.9%), Cardiovascular (26.3%), and Diuretics (16.3%)—aligns with prevalent health concerns in France. The high import values of Metformin, Irbesartan, and Hydrochlorothiazide indicate a strong market demand for these medications. This demand is driven by the significant prevalence of diabetes, hypertension, and related cardiovascular conditions among the French population. By focusing on these therapeutic areas, CSP Mylan SAS AT Csp- Labo 274 addresses critical healthcare needs, ensuring the availability of essential treatments for chronic conditions.

2Sourcing Profile

CSP Mylan SAS AT Csp- Labo 274's sourcing strategy emphasizes the procurement of generic drugs, particularly from India, which is known

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — CSP Mylan SAS AT Csp- Labo 274,

What products does CSP Mylan SAS AT Csp- Labo 274, import from India?

CSP Mylan SAS AT Csp- Labo 274, imports 6 pharmaceutical products across 5 categories. Top imports: Metformin ($3.3M), Irbesartan ($2.1M), Hydrochlorothiazide ($1.3M), Ezetimibe ($600.0K), Sitagliptin ($500.0K).

Who supplies pharmaceuticals to CSP Mylan SAS AT Csp- Labo 274, from India?

CSP Mylan SAS AT Csp- Labo 274, sources from 5 verified Indian suppliers. The primary supplier is Mylan Laboratories Limited (89.1% of imports, $14.2M).

What is CSP Mylan SAS AT Csp- Labo 274,'s total pharmaceutical import value?

CSP Mylan SAS AT Csp- Labo 274,'s total pharmaceutical import value from India is $8.0M, based on 160 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does CSP Mylan SAS AT Csp- Labo 274, focus on?

CSP Mylan SAS AT Csp- Labo 274, imports across 5 categories. The largest: Diabetes & Endocrine (46.9%), Cardiovascular (26.3%), Diuretics (16.3%).

Get Full CSP Mylan SAS AT Csp- Labo 274, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.